Welcome to the Provis Infusion Clinic

The Provis Infusion Clinic is committed to the delivery of patient-focused services to assist physicians in the management of their patients.

At Provis Infusion Clinic we provide chemotherapy and other infusion services for treatments that are currently not covered under Ontario’s provincial health insurance plan thereby allowing physicians and their patients increased access to certain medications.

Our individualized service is delivered by highly trained professional staff in a non-institutional, friendly environment while operating under the highest standards and observing the Canada Health Act.

Patient safety is paramount to our service offering – we operate in a similar manner to a hospital chemotherapy unit. All infusions are performed by highly skilled oncology nurses, supervised by an on-site physician. All medication are compounded on-site, by pharmacy technicians, under a bio-hazard hood, supervised by oncology pharmacists.

Provis Infusion Clinic is a private Canadian corporation, not affiliated with any other organization or institution.

We look forward to being of service to you.

Sincerely,

Graham Vincent, President
The Provis Infusion Clinic

Welcome to the new Provis Website

We are pleased to offer this new website for your information and use. Please copy or click www.provisinfusion.com and update your web browser.
.

The Ride to Conquer Cancer

The Provis Pelotons Cycling Team will be participating in the Ride to Conquer Cancer - June 7th and 8th, 2014. The ride is over 200km's from Toronto to Niagara Falls. To date the team has raised close to $10,000 for cancer research. Go Manny, Naz, and Graham.

ASCO News – Early use of docetaxel with hormone therapy prolongs survival in prostate cancer trial

Study results presented at the ASCO annual meeting suggest that adding docetaxel to standard hormone therapy as part of first-line treatment for men with newly diagnosed, advanced hormone-sensitive prostate cancer can extend survival, compared with chemotherapy alone. Lead author Christopher Sweeney noted "this is the first study to identify a strategy that prolongs survival in newly diagnosed metastatic prostate cancer," adding that "the benefit is substantial and warrants this being a new standard treatment."
http://www.firstwordpharma.com/node/1214202#axzz33a0EwLJQ

Non-Muscle Invasive Bladder Cancer

Provis works with the University Urology Associates (UUA), in providing the compounded MMC for electronically stimulated Mitomycin-C (EMDA MMC) to treat non-muscle invasive bladder cancer.

New Combined-Therapy Option For Metastatic Pancreatic Cancer

Adcetris® Receives Funding from Cancer Care Ontario

Adcetris® (Brentuximab) has been funded by CCO for use in patients with Hodgkin's lymphoma who have relapsed disease following autologous stem cell transplant.

Kadcyla® is now offered at the Provis Infusion Clinic

Kadcyla® is a single agent for the treatment of people with HER2-positive metastatic breast cancer (mBC) who received both prior treatment with HERCEPTIN® (trastuzumab) and a taxane, separately or in combination.

Provis Infusion Interactive Tour

Interested in viewing the Provis Infusion Clinic? Click on the link below to access the interactive tour.